Francesco Saladini
Overview
Explore the profile of Francesco Saladini including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
68
Citations
607
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Papaioannu Borjesson R, Zazzi M, Saladini F, Santoro M, Armenia D, Spagnuolo V, et al.
New Microbiol
. 2024 Nov;
47(3):298-302.
PMID: 39560045
Due to a limited range of effective treatment options, highly treatment-experienced (HTE) people with HIV (PWH) still struggle to maintain virological suppression and obtain an adequate immunological recovery. To increase...
2.
Biba C, Fiaschi L, Varasi I, Paletti C, Bartolini N, Zazzi M, et al.
Viruses
. 2024 Sep;
16(9).
PMID: 39339940
Background: Next-generation sequencing (NGS) kits are needed to finalise the transition from Sanger sequencing to NGS in HIV-1 genotypic drug resistance testing. Materials And Methods: We compared a homemade NGS...
3.
Armenia D, Carioti L, Micheli V, Bon I, Allice T, Bonura C, et al.
Viruses
. 2024 Sep;
16(9).
PMID: 39339898
Background: Next-generation sequencing (NGS) is gradually replacing Sanger sequencing for HIV genotypic drug resistance testing (GRT). This work evaluated the concordance among different NGS-GRT interpretation tools in a real-life setting....
4.
Monti B, Soria A, Saladini F, Lapadula G, Squillace N, Giammarino F, et al.
J Med Virol
. 2024 Jul;
96(8):e29832.
PMID: 39056225
No abstract available.
5.
Panza F, Saladini F, Bartolini N, Gianmarino F, Montagnani F, Spagnuolo V, et al.
New Microbiol
. 2024 May;
47(1):116-122.
PMID: 38700893
Management of virological failure in heavily treatment-experienced people with multidrug-resistant (MDR) HIV infection is a serious clinical challenge. New drugs with novel mechanisms of action have recently been approved, and...
6.
Fiaschi L, Biba C, Varasi I, Bartolini N, Paletti C, Giammarino F, et al.
Viruses
. 2024 Feb;
16(2).
PMID: 38399944
Combination antiviral therapy may be helpful in the treatment of SARS-CoV-2 infection; however, no clinical trial data are available, and combined use of direct-acting antivirals (DAA) and monoclonal antibodies (mAb)...
7.
Giammarino F, De Salazar A, Malet I, Vinuela L, Fuentes A, Saladini F, et al.
J Infect Dis
. 2024 Jan;
229(6):1796-1802.
PMID: 38206187
Background: Limited data are available regarding the susceptibility of the reverse transcriptase V106 polymorphism to doravirine. Methods: Doravirine susceptibility was measured in site-directed mutants (SDMs) containing V106I, V106A, V106M, and...
8.
Rossetti B, Incardona F, Di Teodoro G, Mommo C, Saladini F, Kaiser R, et al.
Trop Med Infect Dis
. 2023 May;
8(5).
PMID: 37235291
The EuResist cohort was established in 2006 with the purpose of developing a clinical decision-support tool predicting the most effective antiretroviral therapy (ART) for persons living with HIV (PLWH), based...
9.
Rhee S, Schapiro J, Saladini F, Zazzi M, Khoo S, Shafer R
AIDS Res Ther
. 2023 Feb;
20(1):8.
PMID: 36750835
Background: Doravirine has a unique resistance profile but how this profile might increase its usefulness beyond first-line therapy in persons with susceptible viruses has not been well studied. We sought...
10.
Saladini F, Giammarino F, Maggiolo F, Ferrara M, Cenderello G, Celesia B, et al.
Int J Antimicrob Agents
. 2023 Jan;
61(3):106737.
PMID: 36708743
Objectives: Doravirine shows a rather distinct resistance profile within the nonnucleoside reverse transcriptase inhibitor (NNRTI) class. This study aimed to evaluate the phenotypic susceptibility to doravirine, rilpivirine and etravirine in...